Since BRCA1-mutant breast cancers harbor a defect in their DNA repair machinery leading to a dependency on alternative repair pathways, synthetic lethal therapies show high potential in this genetic context as highlighted by the clinical use of PARP inhibitors to treat BRCA1/2-mutant breast and ovarian cancer [12, 27, 28]. This evidence concerns the gene PARP1 and breast cancer.